Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 4/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | CDC25A | P30304 | 2/20 | 0.59 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.58 |
| ▸ | POLA1 | P09884 | 1/20 | 0.58 |
| ▸ | ST6GAL1 | P15907 | 2/20 | 0.55 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.54 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | CASP7 | P55210 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.54 |
| ▸ | BLM | P54132 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | MDM4 | O15151 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4735308 | 0.90 | VDR (0.58) | VDRUSP2CDC25AABCC4POLA1 | |
| SCHEMBL4739235 | 0.89 | CDC25A (0.61) | VDRUSP2CDC25AABCC4POLA1 | |
| SCHEMBL4739495 | 0.89 | VDR (0.57) | VDRUSP2CDC25AABCC4POLA1 | |
| SCHEMBL21927842 | 0.89 | VDR (0.57) | VDRUSP2CDC25AABCC4POLA1 | |
| SCHEMBL4738787 | 0.88 | VDR (0.79) | VDRUSP2CDC25AABCC4POLA1 | |
| SCHEMBL4738784 | 0.88 | VDR (0.79) | VDRUSP2CDC25AABCC4POLA1 | |
| SCHEMBL4739418 | 0.87 | CDC25A (0.61) | VDRUSP2CDC25AABCC4POLA1 | |
| SCHEMBL4740584 | 0.87 | VDR (0.56) | VDRUSP2CDC25AABCC4POLA1 | |
| SCHEMBL21928678 | 0.87 | CDC25A (0.76) | VDRUSP2CDC25AABCC4POLA1 | |
| SCHEMBL3189894 | 0.87 | ABCC4 (0.78) | VDRUSP2ABCC4ST6GAL1GRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200129445-A1 | LIPID NANOPARTICLE FORMULATION | ARES CAPITAL CORPORATION, AS AGENT | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200129445-A1 | LIPID NANOPARTICLE FORMULATION | TTPA, SREBF1, SREBF2 | VDR 56/4885USP2 2798/4885CDC25A 4087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.